Literature DB >> 27659839

Detection of clonal heterogeneity and targetable mutations in myeloid sarcoma by high-throughput sequencing.

Cedric Pastoret1,2,3,4, Roch Houot2,3,4,5, Francisco Llamas-Gutierrez6, Marie-Laure Boulland1, Tony Marchand2,3,4,5, Patrick Tas6, Beatrice Ly-Sunnaram1, Virginie Gandemer4,7,8, Thierry Lamy2,3,4,5, Mikael Roussel1,2,3,4, Thierry Fest1,2,3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27659839     DOI： 10.1080/10428194.2016.1225208

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  8 in total

1.  Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.

Authors:  Jonas Samuel Jutzi; Titiksha Basu; Maximilian Pellmann; Sandra Kaiser; Doris Steinemann; Mathijs A Sanders; Adil S A Hinai; Annelieke Zeilemaker; Sarolta Bojtine Kovacs; Christoph Koellerer; Jenny Ostendorp; Konrad Aumann; Wei Wang; Emmanuel Raffoux; Bruno Cassinat; Lars Bullinger; Brigitte Schlegelberger; Peter J M Valk; Heike Luise Pahl
Journal:  Blood       Date:  2019-02-12       Impact factor: 22.113

2.  Hoxa11-mediated reduction of cell migration contributes to myeloid sarcoma formation induced by cooperation of MLL/AF10 with activating KRAS mutation in a mouse transplantation model: Hoxa11 in myeloid sarcoma formation.

Authors:  Jen-Fen Fu; Chih-Jen Wen; Tzung-Hai Yen; Lee-Yung Shih
Journal:  Neoplasia       Date:  2022-04-29       Impact factor: 6.218

3.  Loss of RKIP is a frequent event in myeloid sarcoma and promotes leukemic tissue infiltration.

Authors:  Veronica Caraffini; Bianca Perfler; Johannes Lorenz Berg; Barbara Uhl; Silvia Schauer; Karl Kashofer; Nassim Ghaffari-Tabrizi-Wizsy; Herbert Strobl; Albert Wölfler; Gerald Hoefler; Heinz Sill; Armin Zebisch
Journal:  Blood       Date:  2018-01-02       Impact factor: 22.113

4.  RTK-RAS pathway mutation is enriched in myeloid sarcoma.

Authors:  Mihong Choi; Yoon Kyung Jeon; Choong-Hyun Sun; Hong-Seok Yun; Junshik Hong; Dong-Yeop Shin; Inho Kim; Sung-Soo Yoon; Youngil Koh
Journal:  Blood Cancer J       Date:  2018-05-23       Impact factor: 11.037

5.  Extramedullary acute myeloid leukemia (eAML): Retrospective single center cohort study on clinico-pathological, molecular analysis and survival outcomes.

Authors:  Khalid Halahleh; Yazan Alhalaseh; Dalia Al-Rimawi; Waleed Da'na; Kamal Alrabi; Nazmi Kamal; Isra Muradi; Hikmat Abdel-Razeq
Journal:  Ann Med Surg (Lond)       Date:  2021-10-22

6.  Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing.

Authors:  Karl Kashofer; Max Gornicec; Karin Lind; Veronica Caraffini; Silvia Schauer; Christine Beham-Schmid; Albert Wölfler; Gerald Hoefler; Heinz Sill; Armin Zebisch
Journal:  Leuk Lymphoma       Date:  2017-06-20

7.  Newly diagnosed isolated myeloid sarcoma-paired NGS panel analysis of extramedullary tumor and bone marrow.

Authors:  Nils W Engel; Jochim Reinert; Nora M Borchert; Victoria Panagiota; Razif Gabdoulline; Felicitas Thol; Michael Heuser; Walter Fiedler
Journal:  Ann Hematol       Date:  2020-10-27       Impact factor: 3.673

8.  A case report on concurrent occurrence of systemic mastocytosis and myeloid sarcoma presenting with extensive skin involvements and the results of genetic study.

Authors:  Xinye Wang; Lu Zhang; Daobin Zhou; Hao Cai; Xuan Wang; Xianyong Jiang
Journal:  Medicine (Baltimore)       Date:  2020-12-11       Impact factor: 1.817
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.